Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00292916
Other study ID # D-ER-OFZ-200501-Vib
Secondary ID
Status Terminated
Phase Phase 3
First received February 15, 2006
Last updated May 27, 2015
Start date January 2006
Est. completion date July 2007

Study information

Verified date May 2015
Source University of Erlangen-Nürnberg Medical School
Contact n/a
Is FDA regulated No
Health authority Germany: Bayrisches Staatsministerium für Wissenschaft, Forschung und Kunst
Study type Interventional

Clinical Trial Summary

The effect of whole body vibration (WBV) on bone strength and fall frequency in older adults is still vague. Although there is some evidence that WBV may impact Bone Mineral Density in very frail elderly, there is a lack of data concerning the effect of WBV in community-living elderly woman. We hypothesize that WBV significantly affects bone parameters as assessed by DXA, QCT, US and bone markers with parallel positive changes of fall related risk factors (power, strength, balance, and reaction time). We further hypothesize that the effects of WBV were superior to conventional resistance exercise.


Recruitment information / eligibility

Status Terminated
Enrollment 150
Est. completion date July 2007
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 65 Years and older
Eligibility Inclusion Criteria:

- community living elderly females >/=65 years

- live expectation > 2 years

Exclusion Criteria:

- secondary osteoporosis

- CVD-events including stroke

- participation in other studies

- medication and illness affecting bone metabolism within the last 2 years

- medication with impact on falls

- low physical performance (<50 Watt during ergometry)

- excessive alcohol-intake

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Behavioral:
whole body vibration

resistance exercise

"wellness"


Locations

Country Name City State
Germany Institute of Medical Physics Erlangen

Sponsors (4)

Lead Sponsor Collaborator
University of Erlangen-Nürnberg Medical School Institute of Biometrie and Medical Statistics, Netzwerk-Knochengesundheit, Siemens-Betriebskrankenkasse

Country where clinical trial is conducted

Germany, 

References & Publications (4)

Engelke K, Kemmler W, Lauber D, Beeskow C, Pintag R, Kalender WA. Exercise maintains bone density at spine and hip EFOPS: a 3-year longitudinal study in early postmenopausal women. Osteoporos Int. 2006 Jan;17(1):133-42. Epub 2005 Aug 12. — View Citation

Kemmler W, Engelke K, Baumann H, Beeskow C, von Stengel S, Weineck J, Kalender WA. Bone status in elite male runners. Eur J Appl Physiol. 2006 Jan;96(1):78-85. Epub 2005 Oct 26. — View Citation

Kemmler W, Weineck J, Kalender WA, Engelke K. The effect of habitual physical activity, non-athletic exercise, muscle strength, and VO2max on bone mineral density is rather low in early postmenopausal osteopenic women. J Musculoskelet Neuronal Interact. 2004 Sep;4(3):325-34. — View Citation

Stengel SV, Kemmler W, Pintag R, Beeskow C, Weineck J, Lauber D, Kalender WA, Engelke K. Power training is more effective than strength training for maintaining bone mineral density in postmenopausal women. J Appl Physiol (1985). 2005 Jul;99(1):181-8. Epub 2005 Mar 3. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary BMD after 6, 12 and 18 months
Primary strength
Primary power
Secondary balance
Secondary bone markers
See also
  Status Clinical Trial Phase
Completed NCT02781623 - Quantifying Quadriceps Atrophy Following Tibial Plateau Fracture
Completed NCT02497547 - An Efficacy Study of Vagitocin in Postmenopausal Women With Symptoms of Vaginal Atrophy Phase 2
Completed NCT02332343 - Sparing of the Fovea in Geographic Atrophy Progression N/A
Completed NCT00566982 - A Clinical Study to Evaluate the Safety of Ospemifene Phase 3
Completed NCT01586364 - Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus Phase 3
Active, not recruiting NCT05698316 - A Collaborative Resource of Heidelberg Multimodal Imaging of Intermediate and Early Atrophic AMD Cases to Study Prediction of Disease Progression
Recruiting NCT05869812 - Influence of β-hydroxy β-methyl Butyrate (HMB)Supplementation on Post-operative Muscle Mass and Function in Female Athletes Phase 2
Completed NCT02770365 - Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal Atrophy Phase 3
Completed NCT02747641 - Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects N/A
Recruiting NCT02137824 - A Modified Sinus Floor Elevation Technique - a Pilot Study on 12 Patients N/A
Completed NCT01585558 - Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus Phase 3
Completed NCT02868749 - Histology and Ultrasound Pilot Study of HA Gels Adipose Tissue N/A
Recruiting NCT01911312 - Evaluation of Thermal-Aided Muscle Stimulation N/A
Completed NCT00729469 - Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity Phase 3
Completed NCT01553773 - Postmenopausal Facial Skin After Estradiol and Genistein Topical Treatment Phase 2
Recruiting NCT02745366 - Buccal Fat Pad Derived Stem Cells With Cortical Tenting in Posterior Mandible Reconstruction Phase 1
Completed NCT00807508 - Leucine Supplementation in Elderly Men Phase 1/Phase 2
Completed NCT00744094 - Resistance Training in Elderly Phase 1/Phase 2
Terminated NCT00267839 - Effect of Exercise on Risk-factors of Elderly Women Phase 3
Completed NCT00276094 - A Clinical Study to Evaluate Ospemifene in the Treatment of Vulvar and Vaginal Atrophy in Postmenopausal Women Phase 3